Literature DB >> 26366806

Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?

Marc Meili1, Beat Müller1, Prasad Kulkarni2, Philipp Schütz1.   

Abstract

Use of inflammatory biomarkers to guide antibiotic decisions has shown promising results in the risk-adapted management of respiratory tract infections, mainly in the inpatient setting. Several observational and interventional trials have investigated the benefits of procalcitonin (PCT) and C-reactive protein (CRP) testing in primary care. Both markers have shown promising results, although CRP is an inflammatory biomarker while PCT is more specific for bacterial infections. For CRP, point-of-care testing is widely established. Recently, sensitive point-of-care testing for PCT has also become available. A high-quality trial comparing these two markers for the management of patients in primary care is currently lacking. The aim of this paper is to review the existing literature investigating the use of PCT and CRP in primary care. The authors compare their performance for guiding antibiotic stewardship and analyze the cut-off values and endpoints to put these parameters into context in a low-acuity environment.

Entities:  

Keywords:  C-reactive protein; ambulatory care; antibiotic guidance; biomarker; general practice; primary care; procalcitonin

Mesh:

Substances:

Year:  2015        PMID: 26366806     DOI: 10.1586/17476348.2015.1081063

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  9 in total

Review 1.  Overview of procalcitonin in pregnancy and in pre-eclampsia.

Authors:  A Mangogna; C Agostinis; G Ricci; F Romano; R Bulla
Journal:  Clin Exp Immunol       Date:  2019-06-13       Impact factor: 4.330

2.  Characterizing Hand Infections in an Underserved Population: The Role of Diabetic Status in Antibiotic Choice and Infection Location.

Authors:  Andrew J Hayden; Neil V Shah; Sarah G Stroud; Gregory S Penny; Steven A Burekhovich; Aadit T Shah; Erika Kuehn; Andrew Yang; Bassel G Diebo; Steven M Koehler
Journal:  J Hand Microsurg       Date:  2019-06-26

Review 3.  Procalcitonin-guided diagnosis and antibiotic stewardship revisited.

Authors:  Ramon Sager; Alexander Kutz; Beat Mueller; Philipp Schuetz
Journal:  BMC Med       Date:  2017-01-24       Impact factor: 8.775

4.  Human Neutrophil Lipocalin in Activated Whole Blood Is a Specific and Rapid Diagnostic Biomarker of Bacterial Infections in the Respiratory Tract.

Authors:  Per Venge; Ann-Katrin Eriksson; Lena Douhan-Håkansson; Karlis Pauksen
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

5.  Clinical features for diagnosis of pneumonia among adults in primary care setting: A systematic and meta-review.

Authors:  Tha Pyai Htun; Yinxiaohe Sun; Hui Lan Chua; Junxiong Pang
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

Review 6.  Frequency and Types of Healthcare Encounters in the Week Preceding a Sepsis Hospitalization: A Systematic Review.

Authors:  Alexander H Flannery; Chad M Venn; Amanda Gusovsky; Stephanie Henderson; Adam S Kiser; Hallie C Prescott; Chanu Rhee; Chris Delcher; Peter E Morris
Journal:  Crit Care Explor       Date:  2022-02-04

7.  Machine learning-assisted prediction of pneumonia based on non-invasive measures.

Authors:  Clement Yaw Effah; Ruoqi Miao; Emmanuel Kwateng Drokow; Clement Agboyibor; Ruiping Qiao; Yongjun Wu; Lijun Miao; Yanbin Wang
Journal:  Front Public Health       Date:  2022-07-28

8.  Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of Procalcitonin and C-reactive protein.

Authors:  Marc Meili; Alexander Kutz; Matthias Briel; Mirjam Christ-Crain; Heiner C Bucher; Beat Mueller; Philipp Schuetz
Journal:  BMC Pulm Med       Date:  2016-03-24       Impact factor: 3.317

9.  Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use.

Authors:  Patrick Joseph; Eliot Godofsky
Journal:  Open Forum Infect Dis       Date:  2018-02-15       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.